Eli Lilly Buys Migraine Treatment Specialist CoLucid For $960M In Cash

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 18 January, 2017 by The TZ Newswire Staff

Eli Lilly Buys Migraine Treatment Specialist CoLucid For $960M In Cash

From StockNews.com: Eli Lilly and Co (NYSE:LLY) will acquire CoLucid Pharmaceuticals, a maker of a cutting edge migraine headache treatment, for $960 million, the two companies announced this morning.

See also
- Next Article Key Words: Donald Trump: ‘I don’t like tweeting’ but have no plans to quit
- Previous Article Need to Know: This gold play’s breakout looks enticing as Trump swats at the dollar
Editorial Calender

January 2017

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30 31

« Dec Feb »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 18 January, 2017 by The TZ Newswire Staff

Eli Lilly Buys Migraine Treatment Specialist CoLucid For $960M In Cash

See also

Editorial Calender

Recent Tags